For-Profit Trials Show Positive Outcomes More Often Than Non-Profits, JAMA Study Finds
This article was originally published in The Pink Sheet Daily
Analysis finds 49% of trials sponsored by non-profits favored newer treatments compared to 67.2% of trials funded by for-profit organizations.
You may also be interested in...
The International Committee of Medical Journal Editors will require that studies be registered at or before patient enrollment in order to be considered for publication. A Sept. 9 editorial notes that only ClinicalTrials.gov currently fits ICMJE registry criteria.
The firm’s acute migraine treatment Nurtec ODT generated $65m in 2020 after launching a year ago. Biohaven aims for Nurtec to become the leader in what could be a $4bn-$5bn category in the US.
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.